Kodiak Sciences to Present at Upcoming Conferences

Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in two virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 18, where a pre-recorded fireside chat will be available at 12:00 a.m. PT. The second event is the Evercore ISI 4th Annual HealthCONx Conference on December 1, starting at 8:45 a.m. PT. Live webcasts will be accessible in the "Events and Presentations" section of Kodiak's website, with replays available following the events.

PALO ALTO, Calif., Nov. 8, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:

• Jefferies London Healthcare Conference (pre-recorded fireside chat available on Thursday, November 18 at 12:00 a.m. Pacific Time)
• Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1 at 8:45 a.m. Pacific Time

A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Kodiak's ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, Kodiak's bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and Kodiak is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

 

View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301418960.html

SOURCE Kodiak Sciences Inc.

FAQ

When is Kodiak Sciences presenting at the Jefferies London Healthcare Conference?

Kodiak Sciences will present at the Jefferies London Healthcare Conference on November 18 at 12:00 a.m. Pacific Time.

What time is Kodiak Sciences' presentation at the Evercore ISI 4th Annual HealthCONx Conference?

Kodiak Sciences will present at the Evercore ISI 4th Annual HealthCONx Conference on December 1 at 8:45 a.m. Pacific Time.

Where can I watch the presentations by Kodiak Sciences?

The presentations by Kodiak Sciences can be watched live on their website in the "Events and Presentations" section.

What is the focus of Kodiak Sciences?

Kodiak Sciences focuses on developing therapeutics for high-prevalence retinal diseases.

What is Kodiak Sciences' stock symbol?

Kodiak Sciences' stock symbol is KOD.